Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression

Launched by EBIMA CLIFFORD OKUNDAYE · Mar 4, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new drug called QRX-3, which aims to help prevent and treat chronic kidney disease (CKD) from getting worse. CKD is a serious condition that affects millions of people worldwide and can lead to kidney failure, requiring treatments like dialysis. The goal of this study is to see if QRX-3 can improve kidney function and overall health for patients with CKD.

To be eligible for this trial, participants need to have chronic kidney disease and a specific level of kidney function, measured by a test called eGFR, that indicates their kidneys are not working well. They should also have experienced a stable decline in kidney function over the past year. Unfortunately, those with rapid kidney decline or certain other kidney issues won't be able to participate. If someone joins the study, they can expect close monitoring and follow-ups to see how well the drug works for them. This trial is important because it could lead to new treatments that help improve the lives of many people living with kidney disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Inclusion criteria
• • Patient with Chronic kidney disease
• • Estimated Glomerular function by MDRD of less than 60mls/min
• • Patients with declining renal function ( as measured by eGFR by MDRD )
• • Rate of decline of eGFR over the last one year of less than 20%
• • Negative Serology markers for CKD etiology
• • Provider perceived adherence to study follow up
• Exclusion Criteria:
• • Rapid rate of decline in kidney function of \> 20 % over last one year
• • Symptomatic renal failure
• • Presence of any suspected Acute renal failure superimposed
• • Presence of cast , hematuria, or abnormal urinalysis outside of simple UTI
• • No known reversible cause of renal decline